$14.49
+3.4%Valhi, Inc. engages in the chemicals, component products, and real estate management and development businesses in the Asia Pacific, Europe, North America, and internationally. The company's Chemicals segment produces and markets titanium dioxide pigments (TiO2), which are white inorganic pigments used in various applications by paint, plastics, decorative laminate, and paper manufacturers. It offers TiO2 under the KRONOS name through agents and distributors. The company's Component Products segment manufactures mechanical and electrical cabinet locks, and other locking mechanisms for use in ignition systems, mailboxes, file cabinets, desk drawers, tool storage cabinets, vending and cash containment machines, integrated inventory and access control secured narcotics boxes, medical cabinetry security, electronic circuit panels, storage compartments, and gas station security applications. It also provides stainless steel exhaust components, gauges, throttle controls, wake enhancement systems, trim tabs, and related hardware and accessories primarily for performance and ski/wakeboard boats. The company's Real Estate Management and Development segment offers utility services to industrial and municipal customers; owns real properties; and develops land holdings for commercial, industrial, and residential purposes. It also holds marketable securities and other investments. The company was incorporated in 1932 and is based in Dallas, Texas. Valhi, Inc. is a subsidiary of Contran Corporation.
Thin margins leave little room for error. Cost management and pricing strategy are critical.
Operating losses indicate the core business is unprofitable. Requires restructuring or revenue growth.
Net losses indicate the company is burning cash. Sustainability depends on path to profitability.
VHI โข NYSE
| Valhi, Inc. Income Statement | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 | Dec 2015 | Dec 2014 | Dec 2013 | Dec 2012 | Dec 2011 | Dec 2010 | Dec 2009 | Dec 2008 | Dec 2007 | Dec 2006 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
REVENUE | ||||||||||||||||||||
2.1B | 2.1B | 1.9B | 2.2B | 2.3B | 1.8B | 1.9B | 1.8B | 1.9B | 1.6B | 1.5B | 1.9B | 1.9B | 2.1B | 2.1B | 1.3B | 1.3B | 1.6B | 1.6B | 1.7B | |
GROSS PROFIT | ||||||||||||||||||||
(1.8B) | (1.7B) | (1.7B) | (1.7B) | (1.7B) | (1.4B) | (1.5B) | (1.2B) | (1.3B) | (1.3B) | (1.3B) | (1.5B) | (1.7B) | (1.5B) | (1.3B) | (1.1B) | (1.1B) | (1.2B) | (1.2B) | (1.1B) | |
305.7M | 424.5M | 245.2M | 490.4M | 580.2M | 412.1M | 434.6M | 609.2M | 602M | 292.1M | 222.9M | 402.8M | 134.2M | 575.2M | 785.4M | 206.1M | 206.1M | 338.9M | 356.8M | 536.8M | |
OPERATING INCOME | ||||||||||||||||||||
(306.7M) | (258.8M) | (289.2M) | (304M) | (311.9M) | (283.6M) | -192.7M | -370.7M | -362.9M | -81.2M | (5.4M) | (276.1M) | (138.7M) | (273.3M) | (281.7M) | (227.6M) | (227.6M) | (238.5M) | (238.4M) | (229.4M) | |
(312.3M) | (258.8M) | (289.2M) | (317.9M) | (328.9M) | (303.7M) | (310.7M) | (324.5M) | (269.4M) | (260.2M) | (269.7M) | (276.1M) | (375.1M) | (273.3M) | (278.6M) | (227.6M) | (227.6M) | (238.5M) | (238.4M) | (229.4M) | |
(0.0) | (0.0) | (0.0) | (16M) | (17M) | (16M) | (19M) | (16M) | (19M) | (13M) | (16M) | (19M) | (18M) | (19M) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | |
-1M | 165.7M | -44M | 186.4M | 268.3M | 128.5M | 88.7M | 370.7M | 2.2B | 66.2M | -14.8M | 168.7M | 1.7B | 372.5M | 531.8M | -21.5M | -21.5M | 100.4M | 118.4M | 307.4M | |
PRE-TAX INCOME | ||||||||||||||||||||
(57.1M) | (49.9M) | (28.3M) | (27.9M) | (32.5M) | (36.2M) | (40.8M) | (55.7M) | (58.9M) | (58.1M) | (53.6M) | (56.7M) | (56.1M) | (56.3M) | (61.9M) | (66.7M) | (66.7M) | (68.7M) | (64.4M) | (67.6M) | |
-40.6M | -28.1M | -7.3M | -17M | -28.5M | -31.4M | -29.9M | -29.6M | -29.5M | -31.4M | -27.2M | -30.1M | -29.7M | -27.9M | -32.6M | -42.4M | -42.4M | -36.8M | -64.4M | -67.6M | |
-5.6M | (0.0) | (0.0) | -29.9M | -34M | -36.1M | -522.4M | (2.8M) | (2.3M) | (1.5M) | (2.7M) | (1.6M) | (1.2M) | (2.1M) | (3.1M) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | |
-42M | 78.5M | 24.5M | -16.5M | -10.5M | -27.9M | 0.0 | -30.7M | -22.8M | -26.6M | -59.3M | -56.7M | 6M | -71.1M | -61.9M | -3.5M | -67.4M | -78.8M | -64.4M | 105M | |
-43M | 244.2M | -19.5M | 169.9M | 257.8M | 100.6M | 104.7M | 236.2M | 291.8M | 3M | -73.8M | 112M | -217.9M | 301.4M | 469.9M | -88.9M | -88.9M | 21.6M | 54M | 217.5M | |
NET INCOME | ||||||||||||||||||||
(11.9M) | (82.9M) | -24.6M | (36.8M) | (60.1M) | (15.9M) | (26.5M) | -30.7M | -120M | (6M) | (97.3M) | (32.5M) | -91M | (104.8M) | (174.9M) | -50.8M | -50.8M | (16.7M) | (103.2M) | (63.8M) | |
-57.6M | 108M | -9.9M | 87.2M | 127.2M | 55.2M | 78.2M | 262.2M | 207.5M | -15.9M | -133.6M | 53.8M | -98M | 159.8M | 217.5M | -34.2M | -34.2M | -800K | -45.7M | 141.7M |
VHI - Filing history and reports
| Filing Type | Filing Date | Period Ending | Fiscal Year | Actions |
|---|---|---|---|---|
8-K 8-K 2026 N/A | May 21, 2026 | May 21, 2026 | 2026 | |
8-K 8-K 2026 N/A | May 07, 2026 | May 07, 2026 | 2026 | |
10-Q 10-Q 2026 Q1 Q1 | May 07, 2026 | March 31, 2026 | 2026 | |
DEF 14A DEF 14A 2026 N/A | April 01, 2026 | May 21, 2026 | 2026 | |
10-K 10-K 2025 FY FY | March 10, 2026 | December 31, 2025 | 2025 | |
8-K 8-K 2026 N/A | March 10, 2026 | March 10, 2026 | 2026 | |
8-K 8-K 2026 N/A | March 05, 2026 | March 05, 2026 | 2026 | |
8-K 8-K 2025 N/A | December 15, 2025 | December 09, 2025 | 2025 | |
10-Q 10-Q 2025 Q3 Q3 | November 06, 2025 | September 30, 2025 | 2025 | |
8-K 8-K 2025 N/A | November 06, 2025 | November 06, 2025 | 2025 |
Continue your VHI research with focused valuation guides.
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.